文献速递核素与放射性配体治疗放射性药物与辐射防护

儿童软脑膜病变患者接受脑室内131I-omburtamab放射免疫治疗后安全门诊治疗的可行性

Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with 131I-omburtamab for leptomeningeal disease.
PubMed 文献 · EJNMMI Res · 2024-07-31

在机构批准的研究(NCT03275402)中,对软脑膜病变患者经Ommaya储液囊脑室内给予925-1850 MBq(25-50 mCi)的131I-omburtamab,并在儿科门诊中心指定房间内完成。基于患者接触、0.3米和1米处的暴露率及全身清除数据制定个体化辐射防护措施,四个年龄队列的防护持续时间范围为释放后1至10天,最长防护时间约比监管指南建议低78%,工作人员受照剂量远低于年度监管监测阈值。结论为131I-omburtamab可在门诊基础上给药,采用基于患者个体暴露率和生物学清除参数的适当辐射安全防护措施。

要点

  • 经Ommaya储液囊脑室内给予925-1850 MBq(25-50 mCi)131I-omburtamab可在儿科门诊中心指定房间内完成。
  • 给药后患者暴露率在0.3米处为0.16-0.46 µSv/hr/MBq,在1米处为0.03-0.08 µSv/hr/MBq。
  • 四个年龄队列的辐射防护持续时间为释放后1至10天,最长防护时间约比监管指南建议低78%。

核心结论

  • 131I-omburtamab可在门诊基础上给药,采用基于患者个体暴露率和生物学清除参数的适当辐射安全防护措施。

研究设计与样本

  • 在机构批准的研究(NCT03275402)中,经Ommaya储液囊脑室内给予925-1850 MBq(25-50 mCi)的131I-omburtamab,地点为儿科门诊中心指定房间。
  • 为参与患者照护的工作人员提供剂量计,以评估注射期间和给药后的暴露。
  • 给药后30分钟内测量患者接触、0.3米和1米处的暴露率,患者离院后对房间进行监测。
  • 使用美国核管理委员会(US NRC)监管指南建议结合平均暴露率和全身清除估计计算辐射暴露持续时间。
  • 根据暴露率测量和清除数据,按年龄分为四个队列(<3岁、3-10岁、10-18岁、18岁以上)制定患者特异性防护措施。

主要发现

  • 给药后患者暴露率在0.3米处为0.16-0.46 µSv/hr/MBq,在1米处为0.03-0.08 µSv/hr/MBq。
  • 四个评估队列的辐射暴露防护持续时间为释放后1至10天。
  • 基于最高测量暴露率和最慢全身清除,最长防护时间约比监管指南建议低78%。
  • 每次给予131I-omburtamab相关的工作人员辐射暴露远低于个体暴露监测的年度监管阈值。

临床怎么用

  • 原文结论为131I-omburtamab可在门诊基础上给药,采用基于患者个体暴露率和生物学清除参数的适当辐射安全防护措施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiolabeled antibody 131I-omburtamab was administered intraventricularly in patients with leptomeningeal disease under an institutionally approved study (#NCT03275402). Radiation safety precautions were tailored for individual patients, enabling outpatient treatment based on in-depth, evidence-based recommendations for such precautions. The imperative advancement of streamlined therapeutic administration procedures, eliminating the necessity for inpatient isolation and resource-intensive measures, holds pivotal significance. This development bears broader implications for analogous therapies within the pediatric patient demographic. METHODS: Intraventricular radioimmunotherapy (RIT) with 925-1850 MBq (25-50 mCi) of 131I-omburtamab was administered via the Ommaya reservoir, in designated rooms within the pediatric ambulatory care center. Dosimeters were provided to staff involved in patient care to evaluate exposure during injection and post-administration. Post-administration exposure rate readings from the patient on contact, at 0.3 m, and at 1 m were taken within the first 30 min, and the room was surveyed after patient discharge. Duration of radiation exposure was calculated using standard U.S. Nuclear Regulatory Commission (US NRC) regulatory guidance recommendations combined with mean exposure rates and whole-body clearance estimates. Exposure rate measurements and clearance data provided patient-specific precautions for four cohorts by age: < 3 y/o, 3-10 y/o, 10-18 y/o, and 18+. RESULTS: Post-administration exposure rates for patients ranged from 0.16 to 0.46 µSv/hr/MBq at 0.3 m and 0.03-0.08 µSv/hr/MBq at 1 m. Radiation exposure precautions ranged from 1 to 10 days after release for the four evaluated cohorts. Based on the highest measured exposure rates and slowest whole-body clearance, the longest precautions were approximately 78% lower than the regulatory guidance recommendations. Radiation exposure to staff associated with 131I-omburtamab per administration was substantially below the annual regulatory threshold for individual exposure monitoring. CONCLUSION: 131I-omburtamab can be administered on an outpatient basis, using appropriate patient-based radiation safety precautions that employ patient-specific exposure rate and biological clearance parameters. This trial is registered with the National Library of Medicine's ClinicalTrials.gov. The registration number is NCT03275402, and it was registered on 7 September 2017. The web link is included here. https://clinicaltrials.gov/study/NCT03275402 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Prasad K, Serencsits BE, Chu BP, et al. Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with 131I-omburtamab for leptomeningeal disease. EJNMMI Res. 2024. PMID: 39083105. doi:10.1186/s13550-024-01127-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。